Supplementary Table S1: Overview of oral anticancer agents currently approved and available for gynecologic oncology in Germany

	Setting	Drug Class	Medication/Active Substance
Breast Cancer	Adjuvant	CDK4/6 inhibitors	Abemaciclib, Ribociclib
		Aromatase inhibitors (AI)	Letrozole, Anastrozole, Exemestane
		Selective Estrogen Receptor Modulators (SERM)	Tamoxifen
		PARP inhibitors	Olaparib
		Tyrosine kinase inhibitors	Neratinib
	Metastatic	CDK4/6 inhibitors	Abemaciclib, Palbociclib, Ribociclib
		Aromatase inhibitors (AI)	Letrozole, Anastrozole, Exemestane
		Selective Estrogen Receptor Downregulators (SERD)	Elacestrant
		Oral cytostatics	Capecitabine, Vinorelbine
		PIK3CA inhibitors (AKT pathway inhibitors)	Alpelisib, Capivasertib
		PARP inhibitors	Olaparib, Talazoparib
		mTOR inhibitors	Everolimus
		Tyrosine kinase inhibitors	Tucatinib
Ovarian Cancer	Maintenance (post-first-line and relapse)	PARP inhibitors	Niraparib, Olaparib, Rucaparib